JP2017503810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503810A5 JP2017503810A5 JP2016545917A JP2016545917A JP2017503810A5 JP 2017503810 A5 JP2017503810 A5 JP 2017503810A5 JP 2016545917 A JP2016545917 A JP 2016545917A JP 2016545917 A JP2016545917 A JP 2016545917A JP 2017503810 A5 JP2017503810 A5 JP 2017503810A5
- Authority
- JP
- Japan
- Prior art keywords
- ectodomain
- ntb
- subject
- cell
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 27
- 102100029197 SLAM family member 6 Human genes 0.000 claims 19
- 239000000556 agonist Substances 0.000 claims 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 102000046571 human SLAMF6 Human genes 0.000 claims 8
- 206010033661 Pancytopenia Diseases 0.000 claims 7
- 208000024389 cytopenia Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 238000011534 incubation Methods 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000002627 4-1BB Ligand Human genes 0.000 claims 3
- 108010082808 4-1BB Ligand Proteins 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 2
- 208000033779 X-linked lymphoproliferative disease Diseases 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000004606 Fillers/Extenders Substances 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 206010025327 Lymphopenia Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000050327 human TNFRSF9 Human genes 0.000 claims 1
- 102000051144 human TNFSF9 Human genes 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 231100001023 lymphopenia Toxicity 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925265P | 2014-01-09 | 2014-01-09 | |
| US61/925,265 | 2014-01-09 | ||
| PCT/IL2015/050033 WO2015104711A1 (en) | 2014-01-09 | 2015-01-08 | Improved cell compositions and methods for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020053791A Division JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503810A JP2017503810A (ja) | 2017-02-02 |
| JP2017503810A5 true JP2017503810A5 (OSRAM) | 2018-02-22 |
| JP6682438B2 JP6682438B2 (ja) | 2020-04-15 |
Family
ID=53523593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545917A Active JP6682438B2 (ja) | 2014-01-09 | 2015-01-08 | 癌治療のための改善された細胞組成物および方法 |
| JP2020053791A Active JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020053791A Active JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10344073B2 (OSRAM) |
| EP (2) | EP4101461A1 (OSRAM) |
| JP (2) | JP6682438B2 (OSRAM) |
| AU (1) | AU2015205327B2 (OSRAM) |
| CA (1) | CA2935903A1 (OSRAM) |
| ES (1) | ES2902835T3 (OSRAM) |
| IL (1) | IL246607B (OSRAM) |
| WO (1) | WO2015104711A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7080234B2 (ja) * | 2016-11-23 | 2022-06-03 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | ベンズアミドおよび活性化合物組成物および使用方法 |
| CN107502589A (zh) * | 2017-08-04 | 2017-12-22 | 北京世纪劲得生物技术有限公司 | 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法 |
| US11110171B2 (en) | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| WO2019145956A1 (en) * | 2018-01-25 | 2019-08-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods for improved immunotherapy |
| JP7458318B2 (ja) * | 2018-02-12 | 2024-03-29 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節 |
| IL267614A (en) * | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
| WO2021001653A1 (en) | 2019-07-03 | 2021-01-07 | Oxford Biotherapeutics Ltd | Antibodies and methods of use |
| KR20240131463A (ko) | 2020-05-05 | 2024-08-30 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| EP4146626A4 (en) | 2020-05-05 | 2024-05-29 | Nuvalent, Inc. | CHEMOTHERAPEUTIC AGENTS BASED ON HETEROAROMATIC MACROCYCLIC ETHERS |
| KR20240087788A (ko) | 2021-10-01 | 2024-06-19 | 뉴베일런트, 아이엔씨. | 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US7479269B2 (en) * | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| US6284267B1 (en) | 1996-08-14 | 2001-09-04 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050054051A1 (en) | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP4326944B2 (ja) | 2001-07-19 | 2009-09-09 | イネイト・ファーマ | ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ |
| MXPA04001986A (es) * | 2001-08-29 | 2004-06-07 | Genentech Inc | Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad. |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| JP2005206478A (ja) | 2004-01-20 | 2005-08-04 | Kirin Brewery Co Ltd | 樹状細胞膜分子−ＩｇＦｃ融合ポリペプチドまたはそれに対する抗体を含む医薬組成物 |
| US7592313B2 (en) * | 2004-05-17 | 2009-09-22 | Board Of Trustees Of The University Of Illinois | Method of stimulating proliferation of regulatory T cells in a diabetic mammal |
| ES2319286T3 (es) | 2004-10-02 | 2009-05-06 | Immatics Biotechnologies Gmbh | Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos. |
| EP2083088A3 (en) | 2005-04-07 | 2009-10-14 | Novartis Vaccines and Diagnostics, Inc. | Cancer-related genes |
| KR101279172B1 (ko) * | 2005-08-17 | 2013-06-27 | 다카라 바이오 가부시키가이샤 | 림프구의 제조 방법 |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| TW200823237A (en) | 2006-08-28 | 2008-06-01 | Nuvelo Inc | Antibodies to NTB-A |
| US20110160642A1 (en) | 2007-11-15 | 2011-06-30 | Wolfgang Neuberger | Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases |
| US20120244133A1 (en) * | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| IL267614A (en) | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
-
2015
- 2015-01-08 US US15/110,111 patent/US10344073B2/en active Active
- 2015-01-08 EP EP21197303.7A patent/EP4101461A1/en active Pending
- 2015-01-08 AU AU2015205327A patent/AU2015205327B2/en active Active
- 2015-01-08 EP EP15734922.6A patent/EP3091999B2/en active Active
- 2015-01-08 ES ES15734922T patent/ES2902835T3/es active Active
- 2015-01-08 JP JP2016545917A patent/JP6682438B2/ja active Active
- 2015-01-08 WO PCT/IL2015/050033 patent/WO2015104711A1/en not_active Ceased
- 2015-01-08 CA CA2935903A patent/CA2935903A1/en active Pending
-
2016
- 2016-07-05 IL IL246607A patent/IL246607B/en unknown
-
2019
- 2019-05-20 US US16/417,048 patent/US11530251B2/en active Active
-
2020
- 2020-03-25 JP JP2020053791A patent/JP7004761B2/ja active Active
-
2022
- 2022-11-10 US US18/054,346 patent/US20230078665A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503810A5 (OSRAM) | ||
| Chalan et al. | Thyroid dysfunctions secondary to cancer immunotherapy | |
| Liang et al. | Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell–mediated killing | |
| EP2100615B1 (en) | Cancer therapy | |
| JP6899333B2 (ja) | 汎用キラーｔ細胞 | |
| Chang et al. | Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors | |
| Spaas et al. | Is the combination of immunotherapy and radiotherapy in non-small cell lung cancer a feasible and effective approach? | |
| Lian et al. | Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and Apoptin | |
| Draghiciu et al. | Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination | |
| US10016421B2 (en) | Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination | |
| Reijmen et al. | Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors | |
| Catani et al. | Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma | |
| Lin et al. | (−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) quinic acid inhibits the function of myeloid-derived suppressor cells to enhance the efficacy of anti-pd1 against colon cancer. | |
| Pan et al. | Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site | |
| JP5435938B2 (ja) | ワクチン接種のための天然ペプチド及びそれらの最適化された誘導体の使用 | |
| EP3920899A2 (en) | Immunotherapy for the treatment and prevention of inflammatory bowel disease | |
| Ludwig et al. | Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma | |
| Narita et al. | WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase | |
| Suginobe et al. | Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors | |
| CN103097398B (zh) | 免疫原性肽以及包含该肽的用于预防或治疗hpv相关疾病的组合物 | |
| Gewirtz et al. | The potentially conflicting cell autonomous and cell non-autonomous functions of autophagy in mediating tumor response to cancer therapy | |
| CN108524918B (zh) | 一种抗肿瘤组合物及其表达载体和应用 | |
| Hao et al. | Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors | |
| Cayssials et al. | Beyond tyrosine kinase inhibitors: Combinations and other agents | |
| EP3717013A1 (en) | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |